The investigators sought to evaluate the response to and tolerability of long-term adalimumab use in patients with HS.

After a mean 22.7 months of follow-up, participants showed an 81% reduction in acne lesions, with 60% of participants having 90% or greater reduction.

The researchers determined efficacy based on the change in facial investigator global assessment and changes in total, inflammatory, and noninflammatory lesion counts between baseline and week 16.

The study included women with acne who were started on either spironolactone (n=6684) or an oral tetracycline-class antibiotic (n=31,614) between 2010 and 2016.

The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."

The investigators sought to evaluate the efficacy, safety, and tolerability of red-light (630 nm) PDT with a new 5-aminolevulinic acid "low-dose" topical gel formulation (5%) for the treatment of patients with inflammatory mild to moderate acne vulgaris.

Outcomes were examined in 2 randomized, double-blind, placebo-controlled, parallel-group clinical trials: PIONEER I (ClinicalTrials.gov identifier: NCT01468207) and PIONEER II (ClinicalTrials.gov identifier: NCT01468233).

Patients with hidradenitis suppurativa are at an increased risk for the development of Crohn disease.

Although HAAT is not typically used as a first-line systemic therapy in women with acne, HAAT usage is linked to shorter cumulative antibiotic duration.